colorectal cancer RAS BRAF PSSkit sysmex
Conditions
Interventions
None listed
Sponsors
Kataoka Kozo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically proven for colorectal cancer 2)Clinical Stage III/IV colorectal cancer for which more than 12 cycles of chemotherapy including anti-EGFR therapy is planned. 3)measurable lesions according to RECIST ver1.1 4)No previous history of chemotherapy and radiotherapy 5)Aged 20 years old and over 6)ECOG PS0-1 7)Consent for blood exam for ctDNA analy 8)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Active other malignancies 2)Pregnancy, possible pregnancy or breastfeeding 3)Severe pulmonary fibrosis or emphysema 4)Psychiatric disease 5)Patients requiring systemic steroid medication 6) Grade 2 or greater diarrhea or sensory neuropathy 7)Poorly controlled hypertension 8)History of severe heart disease, heart failure, unstable angina within 6 months or angina attack with 6 months 9) active COVID-19 infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to RAS mutations acquired | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between time to RAS mutations acquired and disease progression, frequencies of BRAF/PIK3CA mutations in ctDNA, disease free survival and overall survival | — |
Contacts
Public ContactMai Fujimori
The Hospital of Hyogo College of Medicine
Outcome results
None listed